{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:49:57Z","timestamp":1782190197120,"version":"3.54.5"},"reference-count":22,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAD"],"published-print":{"date-parts":[[2020,1,6]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>There are over 44 million persons who suffer with Alzheimer\u2019s disease (AD)\nworldwide, no existence of cure and only symptomatic treatments are available for it. The aim of this\nstudy is to evaluate the anti-Alzheimer potential of designed AChEI analogues using computer simulation\ndocking studies. AChEIs are the most potential standards for treatment of AD, because they have\nproven efficacy. Among all AChEIs donepezil possesses lowest adverse effects, it can treat mildmoderate-\nsevere AD and only once-daily dosing is required. Therefore, donepezil is recognized as a\nsignificant prototype for design and development of new drug molecule.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>In this study the Inhibitory potential of the design compounds on acetylcholinesterase enzyme\nhas been evaluated. Docking studies has been performed which further analyzed by in-silico\npharmacokinetic evaluation through pharmacopredicta after that Interaction modes with enzyme active\nsites were determined. Docking studies revealed that there is a strong interaction between the active\nsites of AChE enzyme and analyzed compounds.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>As a result 26 compounds have been indicates better inhibitory activity on AChE enzyme and\nall the screening parameters have also been satisfied by all 26 compounds. From these 26 compounds,\nsix compounds 17, 18, 24, 30, 36 and 56 are found to be the most potent inhibitors of this series by insilico\nstudy through INVENTUS v 1.1 software, having highest bio-affinities i.e. - 8.51, - 7.67, - 8.30,\n- 7.59, - 8.71 and -7.62 kcal\/mol respectively, while the standard or reference drug donepezil had binding\naffinity of - 6.32 kcal\/mol.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Computer aided drug design approach has been playing an important role in the design\nand development of novel anti- AD drugs. With the help of structure based drug design some novel analogues\nof donepezil have been designed and the molecular docking studies with structure based ADME\nproperties prediction studies is performed for prediction of AChE inhibitory activity. The binding\nmode of proposed compounds with target protein i.e. AChE has been evaluated and the resulting data\nfrom docking studies explains that all of the newly designed analogues had significantly high affinity\ntowards target protein compared to donepezil as a reference ligand.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573409915666190301124210","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T12:03:15Z","timestamp":1551700995000},"page":"54-72","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["De-novo Drug Design, Molecular Docking and In-Silico Molecular Prediction of AChEI Analogues through CADD Approaches as Anti-Alzheimer\u2019s Agents"],"prefix":"10.2174","volume":"16","author":[{"given":"Surabhi","family":"Pandey","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences Bhimtal Campus, Kumaun University, Nainital, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.K.","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Kumaun University, Nainital, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1021\/acs.jchemed.6b00596","volume":"94","author":"Daina A.","year":"2017","unstructured":"Daina A.; Blatter M.C.; Baillie Gerritsen V.; Palagi P.M.; Marek D.; Xenarios I.; Drug Design Workshop: A Web-Based Educational Tool To Introduce Computer-Aided Drug Design to the General Public. J Chem Educ 2017,94(3),335-344","journal-title":"J Chem Educ"},{"key":"ref=2","unstructured":"Medical chemistry project. (Accessed from:"},{"key":"ref=3","unstructured":"We speak science. (Accessed from:"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2174\/138620712799361825","volume":"15","author":"Xiang M.","year":"2012","unstructured":"Xiang M.; Cao Y.; Fan W.; Chen L.; Mo Y.; Computer-aided drug design: Lead discovery and optimization. Comb Chem High Throughput Screen 2012,15(4),328-337","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajme.2014.09.006","volume":"51","author":"Ghanemi A.","year":"2015","unstructured":"Ghanemi A.; Alzheimer\u2019s disease therapies: Selected advances and future perspectives. Alexandria Journal of Medicine 2015,51(1),1-3","journal-title":"Alexandria Journal of Medicine"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jalz.2016.12.005","volume":"13","author":"Gustavsson A.","year":"2017","unstructured":"Gustavsson A.; Green C.; Jones R.W.; F\u00f6rstl H.; Simsek D.; de Reydet de Vulpillieres F.; Luthman S.; Adlard N.; Bhattacharyya S.; Wimo A.; Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer\u2019s disease. Alzheimers Dement 2017,13(3),312-321","journal-title":"Alzheimers Dement"},{"key":"ref=7","first-page":"1","volume":"10","author":"Zeb M.W.","year":"2017","unstructured":"Zeb M.W.; Riaz A.; Szigeti K.; Donepezil: A review of pharmacological characteristics and role in the management of alzheimer disease. Clinical Medicine Insights: Geriatrics 2017,10,1-14","journal-title":"Clinical Medicine Insights: Geriatrics"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.20959\/wjpps20174-8726","volume":"6","author":"Gouri K.S.","year":"2017","unstructured":"Gouri K.S.; Dani K.J.; Chowdary K.P.; Evaluation of drug treatment options for Alzheimer\u2019s disease - a review of earlier studies. World J Pharm Pharm Sci 2017,6(4),177-182","journal-title":"World J Pharm Pharm Sci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.cbi.2008.05.031","volume":"175","author":"Sugimoto H.","year":"2008","unstructured":"Sugimoto H.; The new approach in development of anti-Alzheimer\u2019s disease drugs via the cholinergic hypothesis. Chem Biol Interact 2008,175(1-3),204-208","journal-title":"Chem Biol Interact"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3810\/pgm.2012.11.2589","volume":"124","author":"Christensen D.D.","year":"2012","unstructured":"Christensen D.D.; Higher-dose (23 mg\/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer\u2019s disease. Postgrad Med 2012,124(6),110-116","journal-title":"Postgrad Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.ejmech.2015.08.039","volume":"121","author":"Zeng H.","year":"2016","unstructured":"Zeng H.; Wu X.; Alzheimer\u2019s disease drug development based on Computer-Aided Drug Design. Eur J Med Chem 2016,121,851-863","journal-title":"Eur J Med Chem"},{"key":"ref=12","unstructured":"PDB"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"10282","DOI":"10.1021\/jm300871x","volume":"55","author":"Cheung J.","year":"2012","unstructured":"Cheung J.; Rudolph M.J.; Burshteyn F.; Cassidy M.S.; Gary E.N.; Love J.; Franklin M.C.; Height J.J.; Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem 2012,55(22),10282-10286","journal-title":"J Med Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.ejmech.2016.10.042","volume":"124","author":"Sa\u011fl\u0131k B.N.","year":"2016","unstructured":"Sa\u011fl\u0131k B.N.; Ilg\u0131n S.; \u00d6zkay Y.; Synthesis of new donepezil analogues and investigation of their effects on cholinesterase enzymes. Eur J Med Chem 2016,124,1026-1040","journal-title":"Eur J Med Chem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1254\/jjp.89.7","volume":"89","author":"Sugimoto H.","year":"2002","unstructured":"Sugimoto H.; Ogura H.; Arai Y.; Limura Y.; Yamanishi Y.; Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn J Pharmacol 2002,89(1),7-20","journal-title":"Jpn J Pharmacol"},{"key":"ref=16","unstructured":"Chemdraw Software (Accessed from:"},{"key":"ref=17","unstructured":"Novodocker (Accessed from:"},{"key":"ref=18","unstructured":"Inventus (Accessed from:"},{"key":"ref=19","unstructured":"Novo Informatics (Accessed from:"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"Lipinski C.A.","year":"2004","unstructured":"Lipinski C.A.; Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol 2004,1(4),337-341","journal-title":"Drug Discov Today Technol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrd892","volume":"1","author":"Hopkins A.L.","year":"2002","unstructured":"Hopkins A.L.; Groom C.R.; The druggable genome. Nat Rev Drug Discov 2002,1(9),727-730","journal-title":"Nat Rev Drug Discov"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","volume":"2","author":"Pajouhesh H.","year":"2005","unstructured":"Pajouhesh H.; Lenz G.R.; Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2005,2(4),541-553","journal-title":"NeuroRx"}],"container-title":["Current Computer-Aided Drug Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T10:30:46Z","timestamp":1581589846000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170361\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573409915666190301124210","relation":{},"ISSN":["1573-4099"],"issn-type":[{"value":"1573-4099","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}